VerImmune Secures $4.5 Million to Drive Biotech Innovation VerImmune has raised $4.5 million to advance its innovative Virus-Inspired Particle (ViP™) platform technology, which has the potential to transform cancer immunotherapy. [….]
Join ASGCT at the Wyndham Philadelphia Historic District, Oct. 16-17, 2024, for an unparalleled opportunity to immerse yourself in the latest research related to gene and cell therapy for cancer [….]
Adaptimmune Receives U.S. FDA Accelerated Approval for TECELRA® – A New Therapy for Synovial Sarcoma August 2, 2024 Adaptimmune Therapeutics has achieved a significant milestone with the U.S. FDA’s accelerated [….]
A Day in the Life of a Cell Therapy Specialist at Kite, a Gilead Company
Join us for Harnessing the Potential of Antibody Drug Conjugates (ADCs) in Oncology, on October 25 at Johnson & Johnson Innovation – JLABS @ Washington, DC. We’ll host industry thought [….]
With Pandemic in Rearview Mirror, BriaCell Charges Ahead with Cancer Immunotherapy By Mark TerryApril 25, 2023 Many biopharma companies had to place their clinical trials on hold during the first [….]
Chimeric Antigen Receptor T cell (CAR-T) therapies, such as those developed by Kite Pharma, have revolutionized the approach to treating hematological cancers, but the therapies have limitations due to toxicity concerns. Pennsylvania-based BlueSphere Bio believes its approach through the use of TCR-T cell therapies will provide a more precise treatment option for patients.
WASHINGTON – Today, President Biden announced the appointment of seven distinguished clinicians and researchers to the National Cancer Advisory Board, which plays an important role in guiding the Director of the National Cancer Institute in setting the course for the national cancer research program. President Biden is committed to ending cancer as we know it – including by making sure his Administration is investing in research and development that will help advance breakthroughs to prevent, detect, and treat diseases like cancer. The National Cancer Advisory Board will compliment the Administration’s efforts to build on the spirit and learnings of the Cancer Moonshot, which President Biden led in the Obama-Biden Administration.
Ascentage Pharma (6855.HK), a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Innovent Biologics (1801.HK, “Innovent”), today announced a multifaceted strategic collaboration.
Proceeds to Fund Development of Novel RNAi Therapeutics for Cancers, Viral Infections, Fibrosis, and Metabolic Diseases
